The PKD Foundation of Canada is the only national organization solely dedicated to fighting polycystic kidney disease through research, education, advocacy support and awareness. It is essential that the Foundation, supported by all the members of the PKD community in Canada, offers its support to Quebec. In the coming weeks, Quebec will review the only treatment available for PKD for formulary coverage.

In February 2018, the treatment (tolvaptan or JINARC) will be submitted to Institut national d’excellence en santé et services sociaux (INESSS), the provincial entity responsible for the evaluation of medical treatments, for inclusion on the List of Medications of the Régie de l’assurance maladie du Québec (RAMQ).

In this regard, the Foundation is trying to mobilize the PKD community in Quebec to help educate decision-makers to the impact of PKD and the need for this treatment. There are several ways to get involved: Complete a short survey, share your story and become an ambassador. YOUR CONTRIBUTION IS CRITICAL!

The main objective of this campaign is to make the decision-makers more aware of your reality, as well as the challenges of this disease.

For more information on this unique treatment option, visit the learn section.